Advertisement
OVID vs SNDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a Hold and SNDX is a Hold.
OVID's Indicator enters downward trend
The Aroon Indicator for OVID entered a downward trend on October 08, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 250 similar instances where the Aroon Indicator formed such a pattern. In 214 of the 250 cases the stock moved lower. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In 75 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
OVID moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OVID crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Oscillator exited the oversold zone, 20 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 210 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
OVID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.001) is normal, around the industry mean (2.835). P/E Ratio (-10.238) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SNDX sees MACD Histogram just turned negative
SNDX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 39 instances where the indicator turned negative. In 32 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 71 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for SNDX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 223 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SNDX's P/B Ratio (76.292) is slightly higher than the industry average of (2.835). P/E Ratio (-5.139) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
OVID | SNDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 86 | |
P/E GROWTH RATING 1..100 | 24 | 17 | |
SEASONALITY SCORE 1..100 | 49 | 34 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OVID's Valuation (18) in the Pharmaceuticals Major industry is significantly better than the same rating for SNDX (95) in the Biotechnology industry. This means that OVID’s stock grew significantly faster than SNDX’s over the last 12 months.
OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SNDX (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to SNDX’s over the last 12 months.
OVID's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as SNDX (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to SNDX’s over the last 12 months.
OVID's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as SNDX (86) in the Biotechnology industry. This means that OVID’s stock grew similarly to SNDX’s over the last 12 months.
SNDX's P/E Growth Rating (17) in the Biotechnology industry is in the same range as OVID (24) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew similarly to OVID’s over the last 12 months.
| OVID | SNDX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 87% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 82% | 4 days ago 86% |
| Momentum ODDS (%) | 4 days ago 80% | 4 days ago 79% |
| MACD ODDS (%) | N/A | 4 days ago 82% |
| TrendWeek ODDS (%) | 4 days ago 85% | 4 days ago 78% |
| TrendMonth ODDS (%) | 4 days ago 84% | 4 days ago 81% |
| Advances ODDS (%) | 21 days ago 77% | 20 days ago 81% |
| Declines ODDS (%) | 7 days ago 85% | 6 days ago 77% |
| BollingerBands ODDS (%) | 4 days ago 82% | 4 days ago 84% |
| Aroon ODDS (%) | 4 days ago 86% | 4 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OVID’s FA Score shows that 2 FA rating(s) are green while SNDX’s FA Score has 1 green FA rating(s).
- OVID’s FA Score: 2 green, 3 red.
- SNDX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OVID’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).
- OVID’s TA Score: 4 bullish, 5 bearish.
- SNDX’s TA Score: 4 bullish, 4 bearish.
Price Growth
OVID (@Biotechnology) experienced а -12.60% price change this week, while SNDX (@Biotechnology) price change was -24.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
Reported Earning Dates
OVID is expected to report earnings on Nov 11, 2026.
SNDX is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-7.77% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OVID and
Correlation & Price change
A.I.dvisor indicates that over the last year, OVID has been loosely correlated with CLDX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then CLDX could also see price increases.
| Ticker / NAME | Correlation To OVID | 1D Price Change % | ||
|---|---|---|---|---|
| OVID | 100% | -4.87% | ||
| CLDX - OVID | 40% Loosely correlated | -4.84% | ||
| KURA - OVID | 40% Loosely correlated | -6.39% | ||
| SLDB - OVID | 39% Loosely correlated | -3.66% | ||
| SNDX - OVID | 39% Loosely correlated | -5.49% | ||
| DNTH - OVID | 38% Loosely correlated | -3.27% | ||
More | ||||